UBS Assumes Myriad Genetics (MYGN) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $5.57 +0.54%
Rating Summary:
6 Buy, 20 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
6 Buy, 20 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
UBS analyst Douglas Schenkel assumes coverage on Myriad Genetics (NASDAQ: MYGN) with a Neutral rating and a price target of $3.60.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $3.18 yesterday.
You May Also Be Interested In
- Piper Sandler Upgrades Myriad Genetics (MYGN) to Neutral
- JPMorgan Starts Electra (ETRA) at Overweight
- Myriad Genetics to sell prenatal testing unit to Labcorp for $210M
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
